Mangoceuticals, Inc. (MGRX) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
MGRX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Mangoceuticals, Inc. (MGRX) trades at a price-to-earnings ratio of -0.1x, with a stock price of $0.35 and trailing twelve-month earnings per share of $-1.72.
Compared to the Healthcare sector median P/E of 22.1x, MGRX trades at a 100% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, MGRX trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MGRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MGRX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 52.7 | - | -4% | |
| $121M | 24.0 | - | +125%Best | |
| $152B | 155.7 | - | -11% | |
| $5B | 23.1 | 0.29Best | +54% | |
| $151B | 19.5Lowest | - | -4% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See MGRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MGRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MGRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMGRX — Frequently Asked Questions
Quick answers to the most common questions about buying MGRX stock.
Is MGRX stock overvalued or undervalued?
MGRX current P/E: -0.1x. 5-year average P/E: N/A. Percentile: N/A.
How does MGRX's valuation compare to peers?
Mangoceuticals, Inc. P/E of -0.1x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is MGRX's PEG ratio?
MGRX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.